Breaking
🇪🇺 EMA

Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026

Smartee Denti-Technology presents breakthrough mandibular repositioning innovations and European expansion strategy at EAS Congress 2026 in Brussels.

Smartee Denti-Technology Advances Mandibular Repositioning Technology at European Aligner Society Congress 2026

Key Takeaways

  • Smartee Denti-Technology unveiled advanced mandibular repositioning clinical innovations at the 7th European Aligner Society Congress
  • The company detailed its European localization strategy to strengthen market presence across EU dental markets
  • New clear aligner solutions target improved treatment outcomes for complex orthodontic cases requiring jaw repositioning

BRUSSELS, May 3, 2026 — Smartee Denti-Technology, a leading global innovator in clear aligner solutions, presented groundbreaking clinical developments in mandibular repositioning technology at the 7th Congress of the European Aligner Society (EAS) held in Brussels.

Clinical Innovation Focus

The company’s latest presentations centered on advanced mandibular repositioning techniques integrated with their clear aligner platform. These innovations address complex orthodontic cases where traditional aligner therapy alone may be insufficient, particularly for patients requiring simultaneous tooth movement and jaw repositioning.

Dr. Maria Gonzalez, Smartee’s Chief Clinical Officer, highlighted clinical data demonstrating improved treatment predictability and reduced treatment times for Class II malocclusion cases. “Our mandibular repositioning protocol represents a significant advancement in non-surgical orthodontic treatment options,” Gonzalez stated during the presentation.

European Market Expansion

Beyond clinical innovations, Smartee outlined its comprehensive European localization strategy. The initiative includes establishing regional manufacturing capabilities, developing partnerships with European dental laboratories, and implementing region-specific regulatory compliance protocols.

The company plans to open three European distribution centers by Q4 2026, targeting Germany, France, and Italy as primary markets. This expansion aims to reduce delivery times and provide localized customer support for European orthodontists and dental practitioners.

Market Impact and Competition

Smartech’s enhanced mandibular repositioning capabilities position the company to compete more effectively with established players like Align Technology and ClearCorrect in the premium orthodontic segment. Industry analysts estimate the European clear aligner market will reach €2.8 billion by 2027, with complex case treatment representing the fastest-growing segment.

The EAS Congress presentation also featured case studies demonstrating successful outcomes in adult patients with severe Class II division 1 malocclusions, traditionally requiring surgical intervention or fixed appliance therapy.


Frequently Asked Questions

What is mandibular repositioning in orthodontics?

Mandibular repositioning involves gradually moving the lower jaw to a more optimal position relative to the upper jaw, typically used to correct bite problems and improve facial aesthetics without surgery.

When will Smartee’s new technology be available in Europe?

Smartee plans to establish European distribution centers by Q4 2026, with the mandibular repositioning technology expected to be available to European practitioners shortly thereafter.

How does this compare to traditional orthodontic treatments?

Smartee’s clear aligner approach with mandibular repositioning offers a less invasive alternative to surgical jaw correction while providing more comprehensive treatment than traditional aligners alone.

Related Articles

CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device
NewsMay 4, 2026

CVRx Enrolls First Patient in BENEFIT-HF Heart Failure Trial Testing Barostim Device

Sofia Alvarez
Cerus Corporation INTERCEPT Blood System Advances Through European Regulatory Review and Phase 3 Trials
NewsMay 1, 2026

Cerus Corporation INTERCEPT Blood System Advances Through European Regulatory Review and Phase 3 Trials

Matteo Ricci
FDA Real-World Evidence Framework Shifts $10B Toward Validated Medtech Platforms Like VentriPoint
NewsApr 30, 2026

FDA Real-World Evidence Framework Shifts $10B Toward Validated Medtech Platforms Like VentriPoint

Dr. Lukas Schneider
SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization
NewsApr 29, 2026

SQ Innovation's Lasix ONYU Receives CE Marking Approval, Advances Toward European Market Authorization

Oliver Grant